ClinicaliQ Trial Snapshot
- Randomised Treatment of Acute Pancreatitis With Infliximab: Double-blind, Placebo-controlled, Multi-centre Trial (RAPID-I) — Recruiting • Phase II • NCT03684278.
- Infliximab did not improve outcomes in acute pancreatitis compared to placebo in this randomised controlled trial.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study evaluates the effectiveness and safety of infliximab in the treatment of acute pancreatitis in adults. A third of participants will receive one single dose of infliximab via infusion, another third will receive a higher dose of infliximab via infusion and the final third of participants will receive a placebo infusion. Conditions: Acute Pancreatitis Interventions: Infusion of 5 mg/kg Infliximab, Infusion of 10 mg/kg Infliximab, 0.9% Sodium Chloride (Placebo) Lead Sponsor: University of Liverpool Planned Enrollment: 240 participants